Abstract
Borderline ovarian tumor (BOT) is a heterogeneous group of tumors characterized by low malignant potential and atypical proliferation, consisting of 15–20% of all primary ovarian neoplasm. Among BOTs, a subset has a high tendency of relapse probably due to inaccurate subtype stratification and unoptimized care. In this issue of Reproductive Sciences, Wu et al. compared two main BOT subtypes, seromucinous borderline (SMBOT), and mucinous borderline ovarian tumor (MBOT) across many aspects of their clinical pathological features, and identified significant different including tumor growth pattern, tumor sizes, recurrence rate, and the expression Mullerian markers. We reviewed similar work on features of BOT subtypes and highlighted the values added by this study. Future work could be validation with a larger sample size and multicenter design and the application of the identified difference in informing diagnosis and tailored treatment.
This is a preview of subscription content, log in via an institution to check access.
References
Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist. 2012;17(12);1515–33. https://doi.org/10.1634/theoncologist.2012-0139.
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur. J. Cancer. 2013;49(8):1905–14. https://doi.org/10.1016/j.ejca.2013.01.035.
Wu B, Li J, Tao X, Wang J, Zhu G, Lu X, Chen R. Clinicopathological characteristics and prognosis of 91 patients with seromucinous and mucinous borderline ovarian tumors: a comparative study.
Suresh KP, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J. Hum. Reprod. Sci. 2012;5(1):7–13. https://doi.org/10.4103/0974-1208.97779.
Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470:125–42. https://doi.org/10.1007/s00428-016-2040-8.
Acknowledgements
The authors would like to thank Professor Eman Ibrahim of Pathology Department, Ain Shams University for the helpful comments during the drafting of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Laban, M., Chen, X. & Guo, B. Seromucinous and Mucinous Borderline Ovarian Tumors: We Need to Know More. Reprod. Sci. 30, 1684–1685 (2023). https://doi.org/10.1007/s43032-022-01143-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43032-022-01143-2